Overview

the"Fuzheng" Therapy of TCM to Improve the Survival Quality of Early-stage NSCLC by Intervening the CTCs

Status:
Completed
Trial end date:
2019-09-01
Target enrollment:
Participant gender:
Summary
Metastasis is the leading cause of death in patients with lung cancer, and circulating tumor cells(CTCs) play a key role in the process of distant metastasis. The investigators' study will elaborate the clinical significance of CTCs intervented by Traditional Chinese Medicine(TCM) in lung cancer from the diagnosis and clinical staging,metastasis and recurrence, individual treatment and prognosis and so on, in order to provide a new direction for the treatment of lung cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Shanghai University of Traditional Chinese Medicine
Treatments:
Cisplatin
Pemetrexed